Imported cholera with acute renal failure after a short  business-trip to the Philippines, Germany, October 2015 by Slesak, G. et al.
1www.eurosurveillance.org
Rapid communications
Imported cholera with acute renal failure after a short 
business-trip to the Philippines, Germany, October 2015
G Slesak 1 , R Fleck 1 , D Jacob 2 , R Grunow 2 , J Schäfer 1 
1. Tropenklinik Paul-Lechler-Hospital, Tübingen, Germany
2. Robert Koch Institute, Berlin, Germany
Correspondence: Günther Slesak (slesak@tropenklinik.de)
Citation style for this article: 
Slesak G, Fleck R, Jacob D, Grunow R, Schäfer J. Imported cholera with acute renal failure after a short business-trip to the Philippines, Germany, October 2015. Euro 
Surveill. 2016;21(1):pii=30099. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.1.30099 
Article submitted on 01 December 2015 / accepted on 07 January 2016 / published on 07 January 2016
A German businessman developed acute watery diar-
rhoea after a three-day trip to the Philippines. He was 
admitted with severe hypotension and acute renal 
failure, but recovered with rapid rehydration. Vibrio 
cholerae O1 serotype Ogawa was isolated. Physicians 
need to be aware of endemic cholera in Asia includ-
ing the Philippines and consider this in their pre-travel 
advice.
Case report
On 4 November 2015, a 56-year-old German business-
man was hospitalised in Tübingen, Germany, with acute 
watery, non-bloody diarrhoea (6–8x/d, no mucus), 
hypotension, malaise, weight loss of 5 kg and anuria. 
Onset of symptoms i.e. watery diarrhoea (8–12x/d), 
slight nausea and abdominal pain, was on 30 October 
towards the end of his return flight from a short busi-
ness-trip to the Philippines, where he visited Subic Bay 
and Manila from 27 to 29 October. He consulted his 
general practitioner (GP) on 2 November, but his con-
dition deteriorated despite increased oral fluid intake. 
Upon hospital admission he looked unwell, tempera-
ture and heart beats were normal, blood pressure was 
70/50mmHg; his skin was dry, his tongue white but still 
humid; otherwise physical examination was normal. He 
was on antihypertensive medication (amlodipine 10mg, 
candesartan 16mg) and had a history of polycystic kid-
ney syndrome with previously normal kidney function. 
He had not received a cholera vaccination prior to his 
trip. He had only been eating in high standard restau-
rants with a variety of foods including Japanese dinner 
(Sashimi and other raw fish) on 28 October in Subic 
Bay, and briefly cooked/fried seafood on 29 October in 
Makati, Manila. He had neither consumed tap water nor 
drinks with ice cubes. He was started on intravenous 
rehydration therapy immediately, given intravenous 
metoclopramide as antiemetic treatment, and encour-
aged to drink as much as possible.
Laboratory analyses showed creatinine of 4.4 (normal 
range 0.7–1.2mg/dl), urea 80 (normal range 10–50mg/
dl), and slightly increased CRP (13 mg/L; normal range 
0–6mg/L). White blood count showed normal leuco-
cytes (9,860/µl; normal range: 4,000-10,000/µl) with 
only slight neutrophilia (73%; normal range: 50-70%). 
Potassium (3.5mmol/L; normal range: 3.5-5.1mmol/L) 
and sodium (135mmol/L; normal range: 135-145mmol/L) 
were borderline low. Abdominal ultrasound confirmed 
a polycystic kidney disease without further obvious 
changes. With extensive parenteral and oral fluid and 
electrolyte replacement of over  5 L within the first 20 
hours, he started producing urine and kidney function 
normalised rapidly (creatinine on 5 and 6 November, 2 
and 3 day of admission: 2.4 and 1.4mg/dl; urea 72 and 
55mg/dl, respectively). His antihypertensive therapy 
was halted during the whole hospital stay. He remained 
afebrile and diarrhoea ceased slowly.
Stool culture from 2 and 4 November (GP visit and hos-
pital admission, respectively) grew Vibrio cholerae, 
fully sensitive to all standard antibiotics tested for 
cholera (except to nitrofurantoin). Further specification 
revealed O1, Biovar El Tor, Serotype Ogawa, sodB- and 
ctxA-positive by real-time PCR, cholera toxin in vitro 
production was relatively low at ca. 1ng/ml compared 
with > 100 ng/ml by other ctxA-positive isolates [1, data 
not shown]. After receiving the microbiological results, 
the option of antibiotic therapy was discussed with 
the patient and doxycycline (300mg single dose) was 
given. He was discharged on 6 November without diar-
rhoea or fever. Follow-up as outpatient revealed normal 
blood tests, including kidney function tests.
Background
After an absence of cholera cases for more than 25 
years [2] cholera has again become endemic in the 
Philippines since 1961 [3], coinciding with the begin-
ning of the ongoing seventh cholera pandemic [4]. 
Cholera typically occurs in crowded settings with poor 
water and sanitation infrastructure. Travel advice usu-
ally takes into consideration current outbreak reports 
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but imported cholera in returning travellers to Europe 
is rare [5-8]. 
The annual incidence of cholera cases (suspected and 
confirmed) in the Philippines was recently calculated 
at 9.1 per 100,000 individuals but is likely to be higher 
due to under-reporting [2]. Ninety-six per cent of ana-
lysed cholera isolates in the Philippines have been 
of Ogawa serotype and have shown susceptibility to 
first-line antibotics [2]. Case fatality was calculated at 
0.62% and up to 2% in outbreaks in the Philippines [2].
Mortality rates of more than 10% have been observed 
early in cholera epidemics but can be reduced to < 0.2% 
with effective therapy [4]. Severe dehydration and 
hypotension can lead to renal impairment. Early antibi-
otic treatment can decrease and shorten diarrhoea by 
50% and is recommended for patients with moderate 
to severe dehydration [4].
Discussion
There have been no documented cholera cases 
imported to Germany from the Philippines for more 
than 15 years [9]. It is noteworthy that a short busi-
ness trip to and around the capital Manila would not 
be considered to constitute an important risk for chol-
era especially with recent outbreaks being reported 
from more peripheral areas of the Philippines [2], and 
the country being listed among cholera-endemic coun-
tries with the lowest incidence rates [10]. The source 
of infection in the present case presumably was con-
sumption of contaminated raw or undercooked fish or 
seafood in high standard restaurants. 
Besides pre-travel advice on general water and food 
precautions, the German Society for Tropical Medicine 
and International Health (DTG) recommends cholera 
vaccination for travellers to areas with current chol-
era outbreaks [11]. Oral cholera vaccination has also 
been shown to provide some protection against trav-
eller’s diarrhoea [12], but a recent systematic review 
of randomised controlled trials concluded that suf-
ficient evidence is still lacking for its use to protect 
travellers against diarrhoea caused by enterotoxigenic 
Escherichia coli [13].
Antibiotic therapy and microbiological diagnosis cer-
tainly came too late to contribute to the rapid improve-
ment of acute renal failure in our patient, instead 
improvement presumably resulted from simple and 
rapid rehydration therapy. Aggressive fluid therapy 
remains the cornerstone of pre-renal failure manage-
ment in cholera [14]. In view of the patients underlying 
kidney disease and potential benefits from antibiotics 
in reducing fluid loss and duration of fecal excretion 
of the pathogen [15], late antibiotic therapy was still 
performed. 
The presented case demonstrates physicians in Europe 
should be aware of endemic cholera not only in Haiti 
and several African countries but also in certain parts 
of Asia including the Philippines [16] and consider 
this in pre-travel advice. Rapid rehydration therapy is 
needed for returning travellers presenting with acute 
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